Aravind Palraj/X
Sep 19, 2026, 01:24
Aravind Palraj: 2025 EULAR Behçet’s Syndrome Update – 5 Practical Take-Home Points
Aravind Palraj, Senior Resident in Clinical Immunology and Rheumatology at Madras Medical College, shared a post on X:
“2025 EULAR Behçet’s syndrome update — 5 practical take-home points:
- Colchicine remains first-line for recurrent mucocutaneous disease and acute arthritis
- Behçet uveitis needs immunosuppression — glucocorticoids should not be used alone
- Pulmonary or peripheral arterial aneurysm – high-dose glucocorticoids with infliximab; embolisation is preferred over open surgery when intervention is needed
- Venous thrombosis – control inflammation first; anticoagulation is not automatic and pulmonary artery aneurysm must be excluded
- Major organ disease increasingly favors early intensive immunosuppression, often with monoclonal anti-TNF therapy
A useful update across mucocutaneous, ocular, vascular, neurologic and GI Behçet’s disease.”
Other posts featuring Aravind Palraj on Hemostasis Today.
-
Sep 19, 2026, 01:23Chokri Ben Lamine: Cemdisiran in PNH – Why Combine Complement Therapies?
-
Sep 19, 2026, 01:19Stefano Garzon: Comparing DOACs SAPT and DAPT After LAAO
-
Sep 19, 2026, 01:18Elad Asher: What Should a Patient Take after Left Atrial Appendage Occlusion?
-
Sep 19, 2026, 00:48Mahmoud Mehawed: Heparin vs Warfarin vs DOACs Understanding the Key Differences
-
Sep 18, 2026, 17:48Ronak H. Mistry: Updated ASH Guidelines Bring New Focus to Iron Deficiency
-
Sep 18, 2026, 17:32Hassan Kawtharany: New Ferritin Cutoffs for the Diagnosis of Iron Deficiency With or Without Anemia
-
Sep 18, 2026, 17:20Abhishek G P: GAVE as an Important Cause of Chronic Gastrointestinal Blood Loss
-
Sep 18, 2026, 17:08Irem Karaman Sebin: ASH 2026 Changes a Key Concept in Iron Deficiency
-
Sep 18, 2026, 16:51Adarsh Krishnan Sundara Rajan: Is VTE the Most Underdiagnosed Critical Threat in Modern Healthcare?